메뉴 건너뛰기




Volumn 16, Issue 6, 2005, Pages 667-674

Addition of low-dose tumor necrosis factor-α to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats

Author keywords

Doxil; Doxorubicin; Osteosarcoma; Rat; Systemic treatment; Tumor necrosis factor

Indexed keywords

DOXORUBICIN; LIPOSOME; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; STEALTH LIPOSOMAL DOXORUBICIN; UNCLASSIFIED DRUG;

EID: 20844448538     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200507000-00012     Document Type: Article
Times cited : (20)

References (37)
  • 1
    • 0029080640 scopus 로고
    • Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes
    • Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 1995; 62:199-204.
    • (1995) Int J Cancer , vol.62 , pp. 199-204
    • Allen, T.M.1    Newman, M.S.2    Woodle, M.C.3    Mayhew, E.4    Uster, P.S.5
  • 2
    • 0842279809 scopus 로고
    • Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors
    • Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85:6949-6953.
    • (1988) Proc Natl Acad Sci USA , vol.85 , pp. 6949-6953
    • Gabizon, A.1    Papahadjopoulos, D.2
  • 3
    • 0030669086 scopus 로고    scopus 로고
    • Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors
    • Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 1997; 54(suppl 4): 15-21.
    • (1997) Drugs , vol.54 , Issue.SUPPL. 4 , pp. 15-21
    • Gabizon, A.1    Martin, F.2
  • 4
    • 0030579707 scopus 로고    scopus 로고
    • Doxorubicin in sterically stabilized liposomes
    • Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380:561-562.
    • (1996) Nature , vol.380 , pp. 561-562
    • Lasic, D.D.1
  • 5
    • 0037334516 scopus 로고    scopus 로고
    • Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications
    • Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3:319-328.
    • (2003) Int Immunopharmacol , vol.3 , pp. 319-328
    • Maeda, H.1    Fang, J.2    Inutsuka, T.3    Kitamoto, Y.4
  • 6
    • 0000954203 scopus 로고    scopus 로고
    • Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes
    • Lasic DD, Papahadjopoulos D (editors). Amsterdam: Elsevier
    • Mayer LD, Cullis PR, Bally MB. Designing therapeutically optimized liposomal anticancer delivery systems: lessons from conventional liposomes. In: Lasic DD, Papahadjopoulos D (editors): Medical Applications of Liposomes. Amsterdam: Elsevier; 1998, pp. 231-257.
    • (1998) Medical Applications of Liposomes , pp. 231-257
    • Mayer, L.D.1    Cullis, P.R.2    Bally, M.B.3
  • 8
    • 0027242138 scopus 로고
    • Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue
    • Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 1993; 53:3765-3770.
    • (1993) Cancer Res , vol.53 , pp. 3765-3770
    • Wu, N.Z.1    Da, D.2    Rudoll, T.L.3    Needham, D.4    Whorton, A.R.5    Dewhirst, M.W.6
  • 9
    • 18844475615 scopus 로고    scopus 로고
    • Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
    • Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, Le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/ CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37:870-877.
    • (2001) Eur J Cancer , vol.37 , pp. 870-877
    • Judson, I.1    Radford, J.A.2    Harris, M.3    Blay, J.Y.4    Van Hoesel, Q.5    Le Cesne, A.6
  • 10
    • 0031861021 scopus 로고    scopus 로고
    • Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial
    • Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16:2445-2451.
    • (1998) J Clin Oncol , vol.16 , pp. 2445-2451
    • Northfelt, D.W.1    Dezube, B.J.2    Thommes, J.A.3    Miller, B.J.4    Fischl, M.A.5    Friedman-Kien, A.6
  • 11
    • 11144357506 scopus 로고    scopus 로고
    • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
    • O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440-449.
    • (2004) Ann Oncol , vol.15 , pp. 440-449
    • O'Brien, M.E.1    Wigler, N.2    Inbar, M.3    Rosso, R.4    Grischke, E.5    Santoro, A.6
  • 12
    • 0036552104 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer
    • Stebbing J, Gaya A. Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat Rev 2002; 28:121-125.
    • (2002) Cancer Treat Rev , vol.28 , pp. 121-125
    • Stebbing, J.1    Gaya, A.2
  • 13
    • 0032826597 scopus 로고    scopus 로고
    • Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity
    • Bickels J, Manusama ER, Gutman M, Eggermont AM, Kollender Y, Abu-Abid S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999; 25:509-514.
    • (1999) Eur J Surg Oncol , vol.25 , pp. 509-514
    • Bickels, J.1    Manusama, E.R.2    Gutman, M.3    Eggermont, A.M.4    Kollender, Y.5    Abu-Abid, S.6
  • 14
    • 0029738520 scopus 로고    scopus 로고
    • Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
    • Eggermont AM, Schraffordt KH, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-2665.
    • (1996) J Clin Oncol , vol.14 , pp. 2653-2665
    • Eggermont, A.M.1    Schraffordt, K.H.2    Lienard, D.3    Kroon, B.B.4    Van Geel, A.N.5    Hoekstra, H.J.6
  • 15
    • 0009885824 scopus 로고    scopus 로고
    • Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience
    • Eggermont AM, Schraffordt KH, Klausner JM, Kroon BB, Schlag PM, Lienard D, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756-764.
    • (1996) Ann Surg , vol.224 , pp. 756-764
    • Eggermont, A.M.1    Schraffordt, K.H.2    Klausner, J.M.3    Kroon, B.B.4    Schlag, P.M.5    Lienard, D.6
  • 16
    • 0026549021 scopus 로고
    • In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion
    • Lienard D, Lejeune FJ, Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992; 16: 234-140.
    • (1992) World J Surg , vol.16 , pp. 234-1140
    • Lienard, D.1    Lejeune, F.J.2    Ewalenko, P.3
  • 17
    • 0345471470 scopus 로고    scopus 로고
    • Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: A multicenter study
    • Olieman AF, Lienard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 1999; 134: 303-407.
    • (1999) Arch Surg , vol.134 , pp. 303-407
    • Olieman, A.F.1    Lienard, D.2    Eggermont, A.M.3    Kroon, B.B.4    Lejeune, F.J.5    Hoekstra, H.J.6
  • 18
    • 0033952276 scopus 로고    scopus 로고
    • TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
    • van Der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000; 82:973-980.
    • (2000) Br J Cancer , vol.82 , pp. 973-980
    • Van Der Veen, A.H.1    De Wilt, J.H.2    Eggermont, A.M.3    Van Tiel, S.T.4    Seynhaeve, A.L.5    Ten Hagen, T.L.6
  • 19
    • 0034012752 scopus 로고    scopus 로고
    • Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
    • de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82:1000-1003.
    • (2000) Br J Cancer , vol.82 , pp. 1000-1003
    • De Wilt, J.H.1    Ten Hagen, T.L.2    De Boeck, G.3    Van Tiel, S.T.4    De Bruijn, E.A.5    Eggermont, A.M.6
  • 21
    • 0023778218 scopus 로고
    • Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study
    • Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80:1039-1044.
    • (1988) J Natl Cancer Inst , vol.80 , pp. 1039-1044
    • Spriggs, D.R.1    Sherman, M.L.2    Michie, H.3    Arthur, K.A.4    Imamura, K.5    Wilmore, D.6
  • 22
    • 0033836614 scopus 로고    scopus 로고
    • Low-dose tumor necrosis factor-alpha augments antiturnor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats
    • ten Hagen TL, van Der Veen AH, Nooijen PT, van Tiel ST, Seynhaeve AL, Eggermont AM. Low-dose tumor necrosis factor-alpha augments antiturnor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer 2000; 87:829-837.
    • (2000) Int J Cancer , vol.87 , pp. 829-837
    • Ten Hagen, T.L.1    Van Der Veen, A.H.2    Nooijen, P.T.3    Van Tiel, S.T.4    Seynhaeve, A.L.5    Eggermont, A.M.6
  • 23
    • 1342288382 scopus 로고    scopus 로고
    • Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics
    • Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, Seynhaeve AL, et al. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer 2004; 109:442-448.
    • (2004) Int J Cancer , vol.109 , pp. 442-448
    • Brouckaert, P.1    Takahashi, N.2    Van Tiel, S.T.3    Hostens, J.4    Eggermont, A.M.5    Seynhaeve, A.L.6
  • 24
    • 0024309730 scopus 로고
    • Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins
    • Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 1989; 169:1977-1991.
    • (1989) J Exp Med , vol.169 , pp. 1977-1991
    • Brett, J.1    Gerlach, H.2    Nawroth, P.3    Steinberg, S.4    Godman, G.5    Stern, D.6
  • 25
    • 0027053675 scopus 로고
    • Influence of extracellular matrix in tumor necrosis factor-induced increase in endothelial permeability
    • Partridge CA, Horvath CJ, Del Vecchio PJ, Phillips PG, Malik AB. Influence of extracellular matrix in tumor necrosis factor-induced increase in endothelial permeability. Am J Physiol 1992; 263:L627-L633.
    • (1992) Am J Physiol , vol.263
    • Partridge, C.A.1    Horvath, C.J.2    Del Vecchio, P.J.3    Phillips, P.G.4    Malik, A.B.5
  • 26
    • 0029985727 scopus 로고    scopus 로고
    • Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat
    • Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996; 83:551-555.
    • (1996) Br J Surg , vol.83 , pp. 551-555
    • Manusama, E.R.1    Nooijen, P.T.2    Stavast, J.3    Durante, N.M.4    Marquet, R.L.5    Eggermont, A.M.6
  • 27
    • 0024470863 scopus 로고
    • Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice
    • Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989; 49: 5922-5930.
    • (1989) Cancer Res , vol.49 , pp. 5922-5930
    • Mayer, L.D.1    Tai, L.C.2    Ko, D.S.3    Masin, D.4    Ginsberg, R.S.5    Cullis, P.R.6
  • 29
    • 0025334830 scopus 로고
    • Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy
    • Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990; 50:4478-4484.
    • (1990) Cancer Res , vol.50 , pp. 4478-4484
    • Boucher, Y.1    Baxter, L.T.2    Jain, R.K.3
  • 30
    • 0031903379 scopus 로고    scopus 로고
    • Transvascular drug delivery in solid tumors
    • Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol 1998; 8:164-175.
    • (1998) Semin Radiat Oncol , vol.8 , pp. 164-175
    • Yuan, F.1
  • 31
    • 0023788067 scopus 로고
    • Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules
    • Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133:95-109.
    • (1988) Am J Pathol , vol.133 , pp. 95-109
    • Dvorak, H.F.1    Nagy, J.A.2    Dvorak, J.T.3    Dvorak, A.M.4
  • 32
    • 0033302303 scopus 로고    scopus 로고
    • Transport of molecules, particles, and cells in solid tumors
    • Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1:241-263.
    • (1999) Annu Rev Biomed Eng , vol.1 , pp. 241-263
    • Jain, R.K.1
  • 34
    • 0029150245 scopus 로고
    • Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size
    • Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55:3752-3756.
    • (1995) Cancer Res , vol.55 , pp. 3752-3756
    • Yuan, F.1    Dellian, M.2    Fukumura, D.3    Leunig, M.4    Berk, D.A.5    Torchilin, V.P.6
  • 35
    • 0034835602 scopus 로고    scopus 로고
    • Liposomal anthracyclines for breast cancer
    • Sparano JA, Winer EP. Liposomal anthracyclines for breast cancer. Semin Oncol 2001; 28:32-40.
    • (2001) Semin Oncol , vol.28 , pp. 32-40
    • Sparano, J.A.1    Winer, E.P.2
  • 36
    • 0032958135 scopus 로고    scopus 로고
    • Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice
    • Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43:1-7.
    • (1999) Cancer Chemother Pharmacol , vol.43 , pp. 1-7
    • Newman, M.S.1    Colbern, G.T.2    Working, P.K.3    Engbers, C.4    Amantea, M.A.5
  • 37
    • 0029963270 scopus 로고    scopus 로고
    • Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: A new anti-tumour approach
    • Manusama ER, Stavast J, Durante NM, Marquet RL, Eggermont AM. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996; 22:152-157.
    • (1996) Eur J Surg Oncol , vol.22 , pp. 152-157
    • Manusama, E.R.1    Stavast, J.2    Durante, N.M.3    Marquet, R.L.4    Eggermont, A.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.